Teva Pays $235M to GSK after Coreg Patent Trial
A jury in Wilmington, Delaware, ordered Teva Pharmaceutical Industries to pay GlaxoSmithKline more than $235 million for violating a patent of its its blood pressure medicine Coreg, according to a Reuters article.
The jury ruled that Teva infringed the patent with its sales of a generic version of GSK's Coreg with a label saying it could treat chronic heart failure, the story said.
The jury rejected Teva's argument that the patent was invalid.
Read the full story